Acceleron Pharma Inc  

(Public, NASDAQ:XLRN)   Watch this stock  
Find more results for GEORGE A. NADER´┐Ż
32.92
May 22 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range     -
52 week 23.61 - 48.50
Open     -
Vol / Avg. 0.00/195,069.00
Mkt cap 1.08B
P/E     -
Div/yield     -
EPS -1.66
Shares 32.81M
Beta     -
Inst. own 96%
Aug 10, 2015
Q2 2015 Acceleron Pharma Inc Earnings Release (Estimated) - 9:30AM EDT - Add to calendar
May 20, 2015
Acceleron Pharma Inc at UBS Global Healthcare Conference
May 12, 2015
Acceleron Pharma Inc at Bank of America Merrill Lynch Health Care Conference
May 7, 2015
Acceleron Pharma Inc at Deutsche Bank Health Care Conference
May 7, 2015
Q1 2015 Acceleron Pharma Inc Earnings Release
May 7, 2015
Q1 2015 Acceleron Pharma Inc Earnings Call - Webcast
Mar 20, 2015
Acceleron Pharma Inc at Biocentury Future Leaders in the Biotech Industry
Mar 2, 2015
Acceleron Pharma Inc at Cowen Health Care Conference
Mar 2, 2015
Q4 2014 Acceleron Pharma Inc Earnings Release
Mar 2, 2015
Q4 2014 Acceleron Pharma Inc Earnings Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '15) 2014
Net profit margin -329.73% -350.32%
Operating margin -340.70% -379.06%
EBITD margin - -337.25%
Return on average assets -32.31% -33.07%
Return on average equity -38.70% -47.88%
Employees 83 -
CDP Score - -

Address

128 SYDNEY STREET
CAMBRIDGE, MA 02139
United States - Map
+1-617-6499200 (Phone)
+1-617-6499988 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Acceleron Pharma Inc. is a clinical stage biopharmaceutical company focused on the discovery, development and commercialization of protein therapeutics for cancer and rare diseases. The Company’s research focuses on the biology of the Transforming Growth Factor-Beta (TGF-b) protein superfamily, a large and diverse group of molecules that are key regulators in the growth and repair of tissues throughout the human body. By coupling its discovery and development expertise, including its knowledge of the TGF-b superfamily, with its internal protein engineering and manufacturing capabilities, it has built a productive research and development platform that has generated clinical and preclinical protein therapeutic candidates with mechanisms of action.

Officers and directors

Francois Nader M.D. Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
John L. Knopf Ph.D. President, Chief Executive Officer, Director
Age: 62
Bio & Compensation  - Reuters
Kevin F. McLaughlin Chief Financial Officer, Senior Vice President, Treasurer
Age: 58
Bio & Compensation  - Reuters
Steven D. Ertel Chief Operating Officer, Executive Vice President
Age: 45
Bio & Compensation  - Reuters
Matthew L. Sherman M.D. Executive Vice President and Chief Medical Officer
Age: 56
Bio & Compensation  - Reuters
Ravindra Kumar Ph.D Chief Scientific Officer, Vice President
Age: 55
Bio & Compensation  - Reuters
John D. Quisel J.D., Ph.D. Vice President, General Counsel, Secretary
Age: 43
Bio & Compensation  - Reuters
Terrence C. Kearney Director
Age: 60
Bio & Compensation  - Reuters
Jean M. George Independent Director
Age: 57
Bio & Compensation  - Reuters
George S. Golumbeski Ph.D. Independent Director
Age: 57
Bio & Compensation  - Reuters